Kura Oncology, Inc. (NASDAQ:KURA) tinted loss of -6.9% (-0.97 points) to US$13.08. The volume of 0.29 Million shares climbed down over an trading activity of 262.79 Million shares. EPS ratio determined by looking at last 12 month figures is -1.67. Over the same time span, the stock marked US$24.02 as its best level and the lowest price reached was US$10.2. The corporation has a market cap of US$487.75 Million.
Kura Oncology, Inc. (NASDAQ:KURA)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -44.8 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 77.3 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 4 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.5. 4 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Manitex International, Inc. (NASDAQ:MNTX) is worth US$124.12 Million and has recently fallen -14.03% to US$6.31. The latest exchange of 0.07 Million shares is below its average trading activity of 48.76 Million shares. The day began at US$6.53 but the price moved to US$6.16 at one point during the trading and finally capitulating to a session high of US$6.53. The stock tapped a 52-week high of US$13.26 while the mean 12-month price target for the shares is US$13.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 1.25, and a price to sales ratio of 0.5. For the past 5 years, the company’s revenue has grown 0.8%, while the company’s earnings per share has grown -21.5%. With an institutional ownership near 59.1%, it carries an earnings per share ratio of -0.17.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.